Mohammad Mahfuzul Haque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Mahfuzul Haque has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Dennis J. Stuehr
Department of Inflammation and Immunity, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
27 shared publications - Jianxun Song
Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, USA
12 shared publications - Jesús Tejero
Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, 15260, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
11 shared publications Dennis J. Stuehr
Inflammation and Immunity, Lerner Research Institute. Cleveland Clinic, OH, USA
8 shared publicationsDennis Stuehr
6 shared publicationsMekki Bayachou
The Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115
6 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
Synthesis, characterization, antifungal, Ct-DNA binding, catalytic activity, DFT and molecular docking studies of transition metal complexes derived from quinoline based ligand
In this work, we effectively prepared and characterized new ligand 1a its Cu(II) complexes (2a-2e), Cr(III), Fe(III), and Co(II) complexes (2f-2h). The synthesized quinoline based ligand 1a and its metal complexes (2a-2h) were investigated using FT-IR, UV-Vis., NMR, EPR spectroscopy and mass spectrometry. Ligand 1a and its metal complexes (2a-2f) were also tested in vitro for antifungal efficacy and Hydrolytic enzyme secretion against Candida strains. Compounds 1a and 2b showed notable activity against C. albicans, with MIC of 250 and 500 μg/mL respectively. Cytotoxicity of test compounds 1a and 2b was carried out by MTT assay. Interaction of compounds 1a and 2b with Ct-DNA was studies using absorption, emission titration, circular dichroism, cyclic voltammetry and viscosity measurements. The binding constant (Kb) for 1a and 2b are -4.79 x 104 and -5.99 x 104 kcal mol-1 and 8.39 x 103 and 10.2 x 103 M-1 respectively. The molecular docking investigation of 1a and 2b with PDB Id: 1BNA validated groove binding mode. The molecular arrangement of active compounds 1a and Cu(II) complex 2b were examined employing DFT studies at the B3LYP/6-311++G(d,p) level to optimize geometry and determine vibrational frequencies. The antioxidant capacity of lead 1a and 2b was evaluated using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and H2O2. The metal complexes 2a-2h were analyzed for catalytic activity and they efficiently facilitated the oxidation of catechol to its corresponding quinone exhibiting turnover numbers following first-order kinetics consistent with Michaelis-Menten enzymatic behavior. The pharmacokinetic characteristics of all the compounds also demonstrated favorable bioavailability.
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSynthesis, characterization, antifungal, Ct-DNA binding, catalytic activity, DFT and molecular docking studies of transition metal complexes derived from quinoline based ligand
In this work, we effectively prepared and characterized new ligand 1a its Cu(II) complexes (2a-2e), Cr(III), Fe(III), and Co(II) complexes (2f-2h). The synthesized quinoline based ligand 1a and its metal complexes (2a-2h) were investigated using FT-IR, UV-Vis., NMR, EPR spectroscopy and mass spectrometry. Ligand 1a and its metal complexes (2a-2f) were also tested in vitro for antifungal efficacy and Hydrolytic enzyme secretion against Candida strains. Compounds 1a and 2b showed notable activity against C. albicans, with MIC of 250 and 500 μg/mL respectively. Cytotoxicity of test compounds 1a and 2b was carried out by MTT assay. Interaction of compounds 1a and 2b with Ct-DNA was studies using absorption, emission titration, circular dichroism, cyclic voltammetry and viscosity measurements. The binding constant (Kb) for 1a and 2b are -4.79 x 104 and -5.99 x 104 kcal mol-1 and 8.39 x 103 and 10.2 x 103 M-1 respectively. The molecular docking investigation of 1a and 2b with PDB Id: 1BNA validated groove binding mode. The molecular arrangement of active compounds 1a and Cu(II) complex 2b were examined employing DFT studies at the B3LYP/6-311++G(d,p) level to optimize geometry and determine vibrational frequencies. The antioxidant capacity of lead 1a and 2b was evaluated using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and H2O2. The metal complexes 2a-2h were analyzed for catalytic activity and they efficiently facilitated the oxidation of catechol to its corresponding quinone exhibiting turnover numbers following first-order kinetics consistent with Michaelis-Menten enzymatic behavior. The pharmacokinetic characteristics of all the compounds also demonstrated favorable bioavailability.
- Open Access
- 23 December 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (1) , 1796-1811
Glutamine Substitution at Lysine 609 in the Autoinhibitory Region Modulates Catalysis, Uncoupling, and Conformational Dynamics of Endothelial Nitric Oxide Synthase
Endothelial nitric oxide synthase (eNOS) is a critically important flavoheme enzyme that synthesizes nitric oxide (NO), a multifunctional signaling molecule essential to vascular homeostasis, immune modulation, and cardiovascular function. Post-translational modifications, such as acetylation, can affect eNOS activity by altering the charge state of lysine residues. However, we presently have little knowledge of how each lysine contributes to catalysis. In this study, we biochemically characterize two conserved lysine residues (Lys609 and Lys733) of eNOS by employing lysine-to-glutamine substitutions (K609Q and K733Q), which neutralize the positive charge at these sites. The K609Q mutant showed an 80% increase in NO production and a better coupling efficiency (∼2.9 vs ∼5.2 in wild-type). This suggests that both electron transfer and enzymatic uncoupling were more effective. This mutant exhibited 1.5-fold enhanced cytochrome c reductase activity and accelerated flavin autoxidation, indicating an increased electron flux through the flavoprotein domain and decreased FMN semiquinone stability. Flavin fluorescence analysis further revealed that K609Q favors a partially open conformational equilibrium that supports enhanced interdomain electron transfer. Ferricyanide reduction remained unchanged across all variants, confirming that FAD-dependent electron transfer is unaffected and that the K609Q substitution specifically modulates FMN-mediated, not FAD-linked, electron flux. Conversely, K733Q exhibited wild-type-like behavior with little to no effect on coupling efficiency and catalysis. Our findings reveal that Lys609 serves a regulatory function in eNOS catalysis. Substitution of this residue enhances coupling efficiency and promotes improved electron transfer. These insights advance our understanding of eNOS enzymology and indicate that the modulation of specific lysine residues, particularly Lys609, may aid in the preservation of endothelial NO production and alleviate the redox imbalance associated with endothelial dysfunction.
- 23 December 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (1) , 1796-1811
Open AccessGlutamine Substitution at Lysine 609 in the Autoinhibitory Region Modulates Catalysis, Uncoupling, and Conformational Dynamics of Endothelial Nitric Oxide Synthase
Endothelial nitric oxide synthase (eNOS) is a critically important flavoheme enzyme that synthesizes nitric oxide (NO), a multifunctional signaling molecule essential to vascular homeostasis, immune modulation, and cardiovascular function. Post-translational modifications, such as acetylation, can affect eNOS activity by altering the charge state of lysine residues. However, we presently have little knowledge of how each lysine contributes to catalysis. In this study, we biochemically characterize two conserved lysine residues (Lys609 and Lys733) of eNOS by employing lysine-to-glutamine substitutions (K609Q and K733Q), which neutralize the positive charge at these sites. The K609Q mutant showed an 80% increase in NO production and a better coupling efficiency (∼2.9 vs ∼5.2 in wild-type). This suggests that both electron transfer and enzymatic uncoupling were more effective. This mutant exhibited 1.5-fold enhanced cytochrome c reductase activity and accelerated flavin autoxidation, indicating an increased electron flux through the flavoprotein domain and decreased FMN semiquinone stability. Flavin fluorescence analysis further revealed that K609Q favors a partially open conformational equilibrium that supports enhanced interdomain electron transfer. Ferricyanide reduction remained unchanged across all variants, confirming that FAD-dependent electron transfer is unaffected and that the K609Q substitution specifically modulates FMN-mediated, not FAD-linked, electron flux. Conversely, K733Q exhibited wild-type-like behavior with little to no effect on coupling efficiency and catalysis. Our findings reveal that Lys609 serves a regulatory function in eNOS catalysis. Substitution of this residue enhances coupling efficiency and promotes improved electron transfer. These insights advance our understanding of eNOS enzymology and indicate that the modulation of specific lysine residues, particularly Lys609, may aid in the preservation of endothelial NO production and alleviate the redox imbalance associated with endothelial dysfunction.
- Open Access
- 27 June 2020
- Published by Elsevier in Redox Biology
- Vol. 36, 101625
Specific O-GlcNAc modification at Ser-615 modulates eNOS function
- 27 June 2020
- Published by Elsevier in Redox Biology
- Vol. 36, 101625
Open AccessSpecific O-GlcNAc modification at Ser-615 modulates eNOS function
- 16 April 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (17) , 9497-9507
Unbiased proteomics identifies plasminogen activator inhibitor-1 as a negative regulator of endothelial nitric oxide synthase
Significance: Endothelial nitric oxide synthase (eNOS) is a fundamental mediator of vascular function influencing cardiovascular homeostasis through the generation of nitric oxide (NO). eNOS activity can be regulated by protein–protein interactions and here using unbiased proteomics, we uncover plasminogen activator inhibitor-1 (PAI-1) as a potent negative regulator of eNOS function. Direct eNOS/PAI-1 binding inhibits NO production and bioavailability. Moreover, knockdown or antagonism of PAI-1 increases NO production. Mechanistically, we show that secreted PAI-1 is endocytosed and interacts with eNOS and pharmacological inhibition of PAI-1 improves endothelial function. Thus, this work identifies a nonproteolytic role for PAI-1, and antagonism of PAI-1 may serve as an approach to promote endothelial function and homeostasis.
- 16 April 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (17) , 9497-9507
Unbiased proteomics identifies plasminogen activator inhibitor-1 as a negative regulator of endothelial nitric oxide synthase
Significance: Endothelial nitric oxide synthase (eNOS) is a fundamental mediator of vascular function influencing cardiovascular homeostasis through the generation of nitric oxide (NO). eNOS activity can be regulated by protein–protein interactions and here using unbiased proteomics, we uncover plasminogen activator inhibitor-1 (PAI-1) as a potent negative regulator of eNOS function. Direct eNOS/PAI-1 binding inhibits NO production and bioavailability. Moreover, knockdown or antagonism of PAI-1 increases NO production. Mechanistically, we show that secreted PAI-1 is endocytosed and interacts with eNOS and pharmacological inhibition of PAI-1 improves endothelial function. Thus, this work identifies a nonproteolytic role for PAI-1, and antagonism of PAI-1 may serve as an approach to promote endothelial function and homeostasis.
- 1 February 2020
- Published by Elsevier in Experimental Hematology
- Vol. 82, 24-32
Effect of nerolidol on cyclophosphamide-induced bone marrow and hematologic toxicity in Swiss albino mice
- 1 February 2020
- Published by Elsevier in Experimental Hematology
- Vol. 82, 24-32
Effect of nerolidol on cyclophosphamide-induced bone marrow and hematologic toxicity in Swiss albino mice
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (8) , 2203-2211
Tyrosine nitration on calmodulin enhances calcium-dependent association and activation of nitric-oxide synthase
- 1 February 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (8) , 2203-2211
Open AccessTyrosine nitration on calmodulin enhances calcium-dependent association and activation of nitric-oxide synthase
- 25 September 2019
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 151,p. e60043
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Hepatitis B virus (HBV) infection is a global health issue. With over 350 million people affected worldwide, HBV infection remains the leading cause of liver cancer. This is a major concern, especially in developing countries. Failure of the immune system to mount an effective response against HBV leads to chronic infection. Although HBV vaccine is present and novel antiviral medicines are being created, eradication of virus-reservoir cells remains a major health topic. Described here is a method for the generation of viral antigen (Ag) -specific CD8+ cytotoxic T lymphocytes (CTLs) derived from induced pluripotent stem cells (iPSCs) (i.e., iPSC-CTLs), which have the ability to suppress HBV replication. HBV replication is efficiently induced in mice through hydrodynamic injection of an HBV expression plasmid, pAAV/HBV1.2, into the liver. Then, HBV surface Ag-specific mouse iPSC-CTLs are adoptively transferred, which greatly suppresses HBV replication in the liver and blood as well as prevents HBV surface Ag expression in hepatocytes. This method demonstrates HBV replication in mice after hydrodynamic injection and that stem cell-derived viral Ag-specific CTLs can suppress HBV replication. This protocol provides a useful method for HBV immunotherapy.
- 25 September 2019
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 151,p. e60043
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Hepatitis B virus (HBV) infection is a global health issue. With over 350 million people affected worldwide, HBV infection remains the leading cause of liver cancer. This is a major concern, especially in developing countries. Failure of the immune system to mount an effective response against HBV leads to chronic infection. Although HBV vaccine is present and novel antiviral medicines are being created, eradication of virus-reservoir cells remains a major health topic. Described here is a method for the generation of viral antigen (Ag) -specific CD8+ cytotoxic T lymphocytes (CTLs) derived from induced pluripotent stem cells (iPSCs) (i.e., iPSC-CTLs), which have the ability to suppress HBV replication. HBV replication is efficiently induced in mice through hydrodynamic injection of an HBV expression plasmid, pAAV/HBV1.2, into the liver. Then, HBV surface Ag-specific mouse iPSC-CTLs are adoptively transferred, which greatly suppresses HBV replication in the liver and blood as well as prevents HBV surface Ag expression in hepatocytes. This method demonstrates HBV replication in mice after hydrodynamic injection and that stem cell-derived viral Ag-specific CTLs can suppress HBV replication. This protocol provides a useful method for HBV immunotherapy.
- 30 August 2019
- Published by Springer Nature in Current Diabetes Reports
- Vol. 19 (10) , 89
Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy
Type 1 diabetes (T1D) is an autoimmune disease in which the immune cells selectively destroy the pancreatic beta (β) cells and results in the deficiency of insulin production. The optimal treatment strategy for T1D should be preventing of β-cell destruction in the pancreas. The purpose of this review is to discuss the immunological therapeutic mechanisms that will help to understand the development and control of β-cell destruction. The review also presents a novel method for development of autoantigen (Ag)-specific regulatory T cells (Tregs) for T1D immunotherapy.
- 30 August 2019
- Published by Springer Nature in Current Diabetes Reports
- Vol. 19 (10) , 89
Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy
Type 1 diabetes (T1D) is an autoimmune disease in which the immune cells selectively destroy the pancreatic beta (β) cells and results in the deficiency of insulin production. The optimal treatment strategy for T1D should be preventing of β-cell destruction in the pancreas. The purpose of this review is to discuss the immunological therapeutic mechanisms that will help to understand the development and control of β-cell destruction. The review also presents a novel method for development of autoantigen (Ag)-specific regulatory T cells (Tregs) for T1D immunotherapy.
- Open Access
- 1 August 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (35) , 12880-12891
Heat shock protein 90 regulates soluble guanylyl cyclase maturation by a dual mechanism
- 1 August 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (35) , 12880-12891
Open AccessHeat shock protein 90 regulates soluble guanylyl cyclase maturation by a dual mechanism
- Open Access
- 1 July 2019
- Published by Elsevier in The Lancet Neurology
- Vol. 18 (7) , 643-652
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
- 1 July 2019
- Published by Elsevier in The Lancet Neurology
- Vol. 18 (7) , 643-652
Open AccessEffects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial